|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Personalized treatment based on mini patient-derived xenografts and WES/RNA sequencing in a patient with metastatic duodenal adenocarcinoma显示文摘Background:Treatment guidelines for a variety of cancers have been increasingly used in clinical practice,and have resulted in major improvement in patient outcomes.However,recommended regimens(even first-line treat-ments)are clearly not ideal for every patients.In the present study,we used mini patient-derived xenograft(mini-PDX)and next-generation sequencing to develop personalized treatment in a patient with metastatic duodenal adenocarcinoma.Methods:Resected metachronous metastatic tumor tissues were implanted into SCID mice to determine the sensitivity to a variety of drug regimens.Mutation profiles were assessed using both DNA whole-exome sequencing(DNA-WES)and RNA sequencing.The results of the analyses were used to select optimal treatment for the patient with metastatic duodenal adenocarcinoma.Results:Assessment with mini-PDX models took only 7 days.The results showed high sensitivity to S-1 plus cis-platin,gemcitabine plus cisplatin and everolimus alone.The patient received gemcitabine plus cisplatin initially,but the treatment was terminated due to toxicity.The patient was then switched to treatment with S-1 alone.The overall disease-free survival was 34 months.DNA-WES and RNA sequencing identified KRAS mutation(A146T),TP53(C229Yfs*10)and RICTOR amplification in the metastatic duodenal adenocarcinoma.These findings provided further support to the results of the mini-PDX,and suggest mTOR inhibitors should be used if and when relapse eventually occurs in this patient.Conclusions:Mini-PDX model combined with WES/RNA sequencing can rapidly assess drug sensitivity in cancer patients and reveal key genetic alterations.Further research on this technology for personalized therapy in patients with refractory malignant tumors is warranted. | Peng Zhao Hui Chen Danyi Wen Shuo Mou Feifei Zhang Shusen Zheng | 2018 | Cancer Communications2018，38，1： | 11 |
| 2 | A meta-analysis of Chinese herbal medicines for vascular dementia显示文摘OBJECTIVE: To investigate the efficacy and safety of Chinese herbal medicines in the treatment of patients with vascular dementia. DATA RETRIEVAL: We retrieved publications from Cochrane Library (2004 to July 2011), PubMed (1966 to July 2011), the Chinese Science and Technique Journals Database (1977 to July 2011), the China National Knowledge Infrastructure (1979 to July 2011), Google Scholar (July 2011), and the Chinese Biomedical Database (1977 to July 2011) using the'Chinese medicine OR Chinese herbal medicine' and 'vascular dementia OR mild cognition impair OR multi-infarct dementia OR small-vessel dementia OR strategic infarct dementia OR hypoperfusion dementia OR hemorrhagic dementia OR hereditary vascular dementia'. SELECTION CRITERIA: Randomized controlled trials comparing Chinese herbal medicines with placebo/western medicine in the treatment of patients with vascular dementia were included. Diagnostic standards included Diagnostic and Statistical Manual of Mental Disorders-IV, and National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherché et l'Enseignement en Neurosciences. Two participants independently conducted literature screening, quality evaluation and data extraction. The quality of each trial was assessed according to the Cochrane Reviewers' Handbook 5.0. MAIN OUTCOME MEASURES: Effective rate, Mini-Mental State Examination scores, Hasegawa Dementia Scale scores, and incidence of adverse reactions. RESULTS: We identified 1 143 articles discussing the effects of Chinese medicine on vascular dementia. Thirty-one of these were included in the analysis. These studies involved a total of 2 868 participants (1 605 patients took Chinese medicine decoctions (treatment group); 1 263 patients took western medicine or placebo). The results of our meta-analysis revealed that Chinese herbal remedies in the treatment group were more efficacious than the control intervention (relative risk (RR)=1.27; 95% confidence interval (CI): 1.18-1.38, P<0.01). Mini-Mental State Examination scores were higher in patients taking Chinese herbal medicines than in those in the control group (weighted mean difference (WMD)=2.83; 95%CI: 2.55-3.12, P<0.01). Patients in the treatment group showed better disease amelioration than those in the control group (Hasegawa Dementia Scale scores; WMD=2.41, 95%CI: 1.48-3.34, P<0.01). There were also considerably fewer adverse reactions among those in the treatment group compared with those in the control group (RR=0.20, 95%CI: 0.08-0.47, P<0.01). CONCLUSION: Chinese herbal medicine appears to be safer and more effective than control measures in the treatment of vascular dementia. However, the included trials were generally low in quality. More well-designed, high-quality trials are needed to provide better evidence for the assessment of the efficacy and safety of Chinese medicines for vascular dementia. | Xiude Qin Yu Liu Yanqing Wu Shuo Wang Dandan Wang Jinqiang Zhu Qiaofeng Ye Wei Mou Liyuan Kang | 2013 | Neural Regeneration Research2013，8，18： | 7 |
| 3 | Mini患者来源异种移植和WES/RNA测序指导一例转移性十二指肠腺癌患者的个体化治疗显示文摘背景与目的各种癌症的治疗指南已越来越多地应用于临床实践,并已极大地改善了患者预后。然而,医生推荐的治疗方案(甚至一线治疗)并非对每位患者都是最佳的。在本研究中,我们应用mini患者来源的异种移植(mini patient-derived xenograft,mini-PDX)和二代测序技术指导了一例转移性十二指肠腺癌患者的个体化治疗。方法将切除的异位转移瘤组织植入SCID小鼠体内,来确定对各种药物的敏感性。采用DNA全外显子测序(DNA whole-exome sequencing,DNA-WES)和RNA测序分析突变谱。所得分析结果用于选择对转移性十二指肠腺癌的最佳治疗方案。结果使用mini-PDX模型进行评估只用了7 d。结果表明,对S-1+顺铂、吉西他滨+顺铂、依维莫司单药具有高敏感性。患者最初接受吉西他滨联合顺铂治疗,但由于毒性而终止治疗。随后,该患者单独使用S-1进行治疗。总无病生存期为34个月。DNA-WES和RNA测序鉴定了转移性十二指肠腺癌中KRAS突变(A146T)、TP53(C229Yfs*10)和RICTOR扩增。这些发现进一步为mini-PDX的结果提供了支持,并建议当该患者最终复发时应使用m TOR抑制剂治疗。结论联合WES/RNA测序的mini-PDX模型可以快速检测癌症患者的药物敏感性,揭示关键的基因变异。有必要进一步研究该技术用以对难治性恶性肿瘤患者进行个体化治疗。 | Peng Zhao Hui Chen Danyi Wen Shuo Mou Feifei Zhang Shusen Zheng | 2019 | 癌症2019，38，7： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员